Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+1.28%+2.62%+51.61%+100.19% 1,014B
+1.10%+1.45%+52.49%+67.37% 644B
+0.58%+3.54%+19.57%+73.56% 464B
-0.36%+4.54%+38.71%+38.21% 354B
+1.52%+3.46%+20.13%+25.75% 265B
+2.41%+5.70%+9.06%+13.60% 253B
+0.91%-0.70%+38.25%+45.67% 203B
+2.48%-2.43%-24.40%-58.09% 186B
+2.17%+4.20%+34.41%+99.41% 183B
Average +0.83%+1.98%+26.65%+45.07% 396.31B
Weighted average by Cap. +0.20%+2.35%+35.35%+61.57%
Logo ElsaLys Biotech
ElsaLys Biotech specializes in the design and development of new-generation antibodies intended to modulate the immune systems of patients suffering from cancer or rare blood diseases. The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!